Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gillette Q3

This article was originally published in The Rose Sheet

Executive Summary

Strong performance of blade and razor division, Duracell battery brand led 17.5% growth in net income to $416 mil. in the third quarter, firm reports Nov. 4. Net sales were up 10.9% to $2.4 bil. Blade and razor sales jumped 17% to $1 bil., driven by Mach3Turbo, Sensor3 and Venus. Personal care sales grew 10% to $236 mil. Advertising blitz supporting both new and existing razors thwarted competition from Energizer, which launched Schick Quattro four-blade men's shaver in September, Gillette claims. The company filed a patent infringement suit against Energizer in August alleging Quattro uses Gillette's proprietary blade technology. A judge heard Gillette's request for a preliminary injunction against Schick Nov. 5-7 in Boston federal court, is expected to issue ruling within the next few weeks...

You may also be interested in...

Energizer Sharpening Schick Quattro, Intuition Promotions For 2004

Energizer is stepping up promotional efforts for its Schick Quattro and Intuition razors, with plans calling for "significant advertising and marketing support" behind the brands in fiscal 2004, particularly in December, the company said in a Nov. 11 sales and earnings 1release

Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?

To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.

Seretide Settlement To Lift Glenmark’s Europe Business

Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts